---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123718"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:55:53.086552+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine secures up to $200M non-dilutive debt facility from Hercules Capital

## Summary
- $200M senior secured term loan facility from Hercules Capital; $30M drawn at closing.
- Up to $80M additional available at Disc's sole discretion through second-half 2026.
- Remaining $90M subject to milestone achievement or lender consent.
- Interest-only for at least 48 months, extendable to 60 months; matures November 2029.
- Proceeds to support bitopertin EPP confirmatory trial, DISC-0974 MF/NDD-CKD studies, and DISC-3405 PV trial.

## SEC filing metadata
- accession: 0000950170-24-123718
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000095017024123718/0000950170-24-123718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000095017024123718/iron-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123718
- JSON: https://secwatch.observer/filing/0000950170-24-123718.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.